July 2026 Catalysts

Investigational varicella vaccine Phase 3 Results Expected

Chickenpox

LM-302 Phase 2 Results Expected

Malignant Neoplasms of Digestive Organs

ESK-001 Phase 2 Results Expected

Plaque Psoriasis

AMG 193 Phase 2 Results Expected

MTAP-deleted NSCLC

Docetaxel Phase 2 Results Expected

Advanced MTAP-null Solid Tumors

INCA034176 Phase 2 Results Expected

Chronic Graft-versus-host-disease

BMS-986435 Phase 2 Results Expected

Heart Failure

Paclitaxel Phase 3 Results Expected

Metastatic Non-Small Cell Lung Cancer

Odronextamab Phase 2 Results Expected

Diffuse Large B-cell Lymphoma (DLBCL)

Carboplatin Phase 3 Results Expected

Carcinoma, Squamous Cell, Non-small-cell Lung

Pemetrexed Phase 3 Results Expected

Carcinoma, Nonsquamous Non-small-cell Lung

Etoposide Phase 3 Results Expected

Carcinoma, Non-Small-Cell Lung

Placebo Phase 3 Results Expected

Type 2 Diabetes Mellitus

Raludotatug Deruxtecan (R-DXd) Phase 2 Results Expected

Gastrointestinal Cancer

Olaparib Phase 3 Results Expected

Ovarian Cancer

Pembrolizumab Phase 3 Results Expected

Non-small Cell Lung Cancer

Cisplatin Phase 3 Results Expected

Gastric Neoplasms

Osimertinib Phase 2 Results Expected

Lung Cancer

AZD6234 Phase 2 Results Expected

Endocrinology

Leniolisib Phase 3 Results Expected

PIDs Linked to PI3K

SAR441344 IV Phase 2 Results Expected

Systemic Lupus Erythematosus

Afimkibart Phase 2 Results Expected

Crohns Disease

Vehicle Cream Phase 3 Results Expected

Prurigo Nodularis

Ruxolitinib Phase 3 Results Expected

MPN (Myeloproliferative Neoplasms)

Placebo Phase 2 Results Expected

Hepatitis B, Chronic

mibavademab Phase 3 Results Expected

Generalized Lipodystrophy

Tezepelumab Phase 3 Results Expected

Moderate to Severe Asthma

BHV-7000 Phase 3 Results Expected

Bipolar Disorder

Placebo Phase 3 Results Expected

Oral Mucositis

GSK5784283 Phase 2 Results Expected

Asthma

Pitolisant tablet Phase 3 Results Expected

Prader-Willi Syndrome

Telisotuzumab vedotin Phase 2 Results Expected

Non-small Cell Lung Cancer

Nirogacestat Phase 2 Results Expected

Ovarian Granulosa-Stromal Tumor

Paclitaxel Phase 2 Results Expected

Carcinoma

REC-4881 Phase 2 Results Expected

AXIN1 Gene Mutation

Bimatoprost SR Phase 3 Results Expected

Open-Angle Glaucoma

PD-1 Monoclonal Antibody Phase 2 Results Expected

Non-small Cell Lung Cancer

BL-B01D1 Phase 2 Results Expected

Small Cell Lung Cancer

Halneuron Phase 2 Results Expected

Chemotherapy Induced Neuropathic Pain

1.0mg/kg/day PRAX-562 Phase 3 Results Expected

Developmental and Epileptic Encephalopathy 1

Hypericin Phase 3 Results Expected

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

VRDN-003 Phase 3 Results Expected

Thyroid Eye Disease

Upadacitinib Phase 3 Results Expected

Ulcerative Colitis (UC)

SION-719 Phase 2 Results Expected

Cystic Fibrosis (CF)

Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Phase 2 Results Expected

Pre-Exposure Prophylaxis of HIV Infection

Lenacapavir Tablet Phase 2 Results Expected

HIV Pre-exposure Prophylaxis

Dostarlimab Phase 2 Results Expected

Neoplasms, Rectal

Carboplatin Phase 2 Results Expected

Primary Peritoneal Carcinoma

Adalimumab Phase 3 Results Expected

Pyoderma Gangrenosum

Sotagliflozin Phase 3 Results Expected

Type 2 Diabetes Mellitus

EVO756 Phase 2 Results Expected

Chronic Spontaneous Urticaria

IAH0968 Phase 3 Results Expected

Stomach Neoplasms

Aleniglipron Phase 2 Results Expected

Obesity, Overweight, or Chronic Weight Management

VRB-101 Phase 2 Results Expected

Obesity

Placebo Phase 3 Results Expected

Carcinoid Syndrome

Lenacapavir Injection Phase 2 Results Expected

Pre-Exposure Prophylaxis of HIV Infection

GTX-102 Phase 3 Results Expected

Angelman Syndrome

povetacicept Phase 2 Results Expected

Lupus Nephritis

Lebrikizumab Phase 3 Results Expected

Atopic Dermatitis

ARO-ALK7 Phase 2 Results Expected

Obesity

Vimseltinib Phase 2 Results Expected

Chronic Graft-Versus-Host Disease (cGVHD)

TAK-360 Phase 2 Results Expected

Idiopathic Hypersomnia

TEV-56248 Phase 3 Results Expected

Asthma

metreleptin Phase 3 Results Expected

Partial Lipodystrophy

Belzutifan Phase 2 Results Expected

Renal Cell Carcinoma

Palbociclib Phase 2 Results Expected

Renal Cell Carcinoma

INCB099280 Phase 2 Results Expected

Advanced Solid Tumor

REGN7544 Phase 2 Results Expected

Postural Orthostatic Tachycardia Syndrome (POTS)

Pembrolizumab Phase 2 Results Expected

Non-small Cell Lung Cancer

PB Phase 2 Results Expected

Sepsis-Induced Hypotension

Placebo Phase 2 Results Expected

Type 2 Diabetes Mellitus

AZD9550 Phase 2 Results Expected

Overweight and Obesity

CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant Phase 3 Results Expected

COVID-19

Olaparib Phase 3 Results Expected

Breast Cancer Metastatic

Bimekizumab Phase 3 Results Expected

Chronic Plaque Psoriasis

TACE+Camrelizumab+Apatinib mesylate Phase 3 Results Expected

Hepatocellular Carcinoma

Recombinant Human Proteoglycan 4 Phase 2 Results Expected

Sjögren's Syndrome

Adagrasib Phase 2 Results Expected

Carcinoma, Non-Small-Cell Lung

mRNA-1345 Phase 3 Results Expected

Respiratory Syncytial Virus

Pembrolizumab Phase 3 Results Expected

Advanced Non-Small Cell Lung Cancer

SSGJ-707 Phase 3 Results Expected

Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

nirmatrelvir Phase 3 Results Expected

COVID-19

ritonavir Phase 3 Results Expected

COVID-19

JSKN003 Phase 2 Results Expected

Advanced Solid Tumor

QRX003, 4% Lotion Phase 3 Results Expected

Netherton Syndrome

HS-20093 Phase 2 Results Expected

Advanced Solid Tumor

Nusinersen Phase 3 Results Expected

Muscular Atrophy, Spinal

Rivoceranib (Apatinib) Phase 3 Results Expected

Hepatocellular Carcinoma (HCC)

Camrelizumab Phase 3 Results Expected

Solid Tumor

BNT162b2 (2025/2026 formulation) Phase 3 Results Expected

COVID-19

oxaliplatin Phase 2 Results Expected